{"nctId":"NCT00133952","briefTitle":"Effect of Ruboxistaurin on Clinically Significant Macular Edema","startDateStruct":{"date":"2005-08"},"conditions":["Diabetic Macular Edema"],"count":309,"armGroups":[{"label":"Ruboxistaurin","type":"EXPERIMENTAL","interventionNames":["Drug: Ruboxistaurin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Ruboxistaurin","otherNames":["LY333531"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 1 or 2 diabetes\n* 18 years or older\n* Hemoglobin A1c (HbA1c) less than or equal to 11%\n* Mild to very severe non-proliferative diabetic retinopathy in the study eye\n* Clinically significant macular edema in the study eye not within 100 microns of center of macula\n\nExclusion Criteria:\n\n* Previous surgery or laser treatment (or need for laser treatment within 3 months) in the study eye\n* Glaucoma in the study eye\n* Unstable cardiovascular disease\n* Major surgery within past 3 months\n* Significantly impaired kidney or liver function, or malignancy requiring chemotherapy or radiation therapy.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Moderate Visual Loss (SMVL) Any Time Baseline Through Month 48","description":"SMVL is defined as a 15 letter or more decrease from baseline in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity that is sustained for the participant's last 6 months of study participation. ETDRS visual acuity uses an eye chart with 5 letters per line. The scores range from 0 (no letters read correctly) to 100 (all letters read correctly).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 24 in Mean Retinal Thickness Within 500 Microns of the Center of the Macula","description":"Least Squares (LS) Mean values were controlled for treatment, pooled center, and baseline value.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":"5.5"},{"groupId":"OG001","value":"9.4","spread":"5.3"}]}]}]},{"type":"SECONDARY","title":"Number of Eyes With Significant Center-Involved Macular Edema at Any Time From Baseline Through Month 24","description":"Significant center-involved macular edema is defined as an absolute retinal thickness at the center of the macula \\>2 standard deviations above the mean baseline value (where the mean and standard deviation are calculated at baseline from the randomized population of participants with retinal thickness values of â‰¤ 300 microns in depth).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Focal Photocoagulation","description":null,"paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 24 in Contrast Sensitivity","description":"Values are presented as changes in the number of letters read correctly on the Pelli-Robson contrast sensitivity chart which consists of 16 triplets (48 letters total) with letters of the same size but decreasing contrast. Least Squares (LS) Mean values were controlled for treatment, pooled center, and baseline value.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"0.4"},{"groupId":"OG001","value":"-0.6","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Month 24 in Retinal Thickness at the Center of the Macula","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":"65.4"},{"groupId":"OG001","value":"13.1","spread":"74.9"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Requiring Focal Photocoagulation at Any Time From Baseline Through Month 24","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Not Requiring Focal Photocoagulation at Any Time From Baseline Through Month 24","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Requiring Repeat Focal Photocoagulation at Any Time From Baseline Though Month 24","description":"Repeat focal photocoagulation is defined as 2 or more focal photocoagulation treatments needed during the study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":31,"n":153},"commonTop":["Headache","Hypertension","Diarrhoea","Influenza","Nasopharyngitis"]}}}